Clinical Trial Update: FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR [Phase 3]

View source ↗

Summary

Phase 3 trial FER-IBD-COR evaluating Ferinject (ferric carboxymaltose) for correcting iron-deficiency anemia in inflammatory bowel disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease
• Iron Deficiency Anemia
• Ulcerative Colitis

Drugs mentioned

• Ferinject (ferric carboxymaltose)

Snippet

Sponsor: Vifor Pharma | Conditions: Inflammatory Bowel Disease, Anemia | Phase 3 | Status: COMPLETED